Information Provided By:
Fly News Breaks for July 29, 2019
ALXN, RARX
Jul 29, 2019 | 08:14 EDT
As previously reported, Raymond James analyst Steven Seedhouse double downgraded RA Pharmaceuticals (RARX) to Market Perform from Strong Buy after the stock's rise to $36 per share from about $5.50 per share in March 2018. While he views zilucoplan as a promising therapy for generalized myasthenia gravis, or gMG, the market is pricing the stock "appropriately" for a drug that appears to be competitive with Alexion's (ALXN) Soliris, Seedhouse tells investors.
News For RARX;ALXN From the Last 2 Days
There are no results for your query RARX;ALXN